Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

TRVI | Trevi Therapeutics, Inc.

IndexRUT P/E- EPS (ttm)-0.34 Insider Own3.69% Shs Outstand98.70M Perf Week0.94%
Market Cap123.31M Forward P/E- EPS next Y-0.41 Insider Trans-0.19% Shs Float61.63M Perf Month-4.04%
Income-27.30M PEG- EPS next Q-0.09 Inst Own82.20% Short Float / Ratio2.13% / 7.20 Perf Quarter-22.46%
Sales- P/S- EPS this Y69.60% Inst Trans56.62% Short Interest1.31M Perf Half Y18.89%
Book/sh0.96 P/B2.23 EPS next Y-28.10% ROA-23.30% Target Price7.33 Perf Year-12.65%
Cash/sh1.63 P/C1.31 EPS next 5Y- ROE-26.40% 52W Range1.43 - 3.50 Perf YTD10.88%
Dividend- P/FCF- EPS past 5Y11.10% ROI- 52W High-38.86% Beta0.76
Dividend %- Quick Ratio21.10 Sales past 5Y- Gross Margin- 52W Low49.65% ATR0.13
Employees25 Current Ratio21.10 Sales Q/Q- Oper. Margin- RSI (14)45.75 Volatility7.14% 5.91%
OptionableYes Debt/Eq0.00 EPS Q/Q64.30% Profit Margin- Rel Volume0.17 Prev Close2.16
ShortableYes LT Debt/Eq0.00 EarningsAug 10 AMC Payout- Avg Volume182.60K Price2.14
Recom1.50 SMA20-3.47% SMA50-5.43% SMA200-8.00% Volume31,020 Change-0.93%
Date Action Analyst Rating Change Price Target Change
Apr-12-23Initiated B. Riley Securities Buy $6
Nov-22-22Initiated SVB Leerink Outperform $6
Jun-03-19Initiated SVB Leerink Outperform $14
Jun-03-19Initiated Stifel Buy $20
Jun-03-19Initiated Needham Buy $18
Jun-03-19Initiated BMO Capital Markets Outperform $15
Sep-06-23 07:30AM
Aug-12-23 08:30AM
Aug-11-23 06:44AM
Aug-10-23 04:05PM
Aug-03-23 04:05PM
07:30AM Loading…
Aug-01-23 07:30AM
Jul-06-23 07:30AM
Jun-04-23 10:45AM
May-30-23 07:30AM
May-22-23 04:05PM
May-16-23 11:46AM
May-12-23 06:38AM
May-11-23 04:05PM
May-10-23 08:48AM
May-09-23 07:30AM
04:05PM Loading…
May-04-23 04:05PM
May-02-23 07:30AM
Apr-27-23 07:30AM
Apr-11-23 04:05PM
Mar-18-23 02:03AM
Mar-17-23 06:19AM
Mar-16-23 04:05PM
Mar-09-23 04:05PM
Mar-08-23 07:30AM
Mar-06-23 04:05PM
Feb-21-23 07:00AM
Feb-16-23 07:30AM
Feb-02-23 07:30AM
Jan-25-23 09:00AM
Jan-05-23 04:05PM
08:26AM Loading…
Dec-26-22 08:26AM
Dec-19-22 04:05PM
Nov-14-22 04:05PM
Nov-10-22 04:05PM
Nov-08-22 07:30AM
Nov-03-22 04:05PM
Oct-27-22 07:30AM
Sep-30-22 09:40AM
Sep-23-22 01:18AM
Sep-22-22 04:01PM
Sep-19-22 09:35AM
Sep-14-22 09:40AM
Sep-07-22 07:30AM
Aug-30-22 04:05PM
Aug-24-22 07:30AM
Aug-22-22 09:30AM
Aug-11-22 04:05PM
Aug-09-22 07:30AM
Aug-04-22 05:41PM
Jul-21-22 06:45AM
Jul-19-22 09:13AM
Jul-14-22 09:00AM
Jul-07-22 07:30AM
Jun-30-22 12:53PM
Jun-29-22 08:37AM
Jun-23-22 10:58AM
Jun-07-22 07:30AM
May-12-22 04:05PM
May-05-22 04:05PM
May-03-22 07:30AM
Apr-13-22 04:25PM
Apr-11-22 08:00AM
Apr-07-22 08:00AM
Apr-05-22 04:25PM
Mar-23-22 03:25PM
Mar-22-22 07:30AM
Mar-17-22 04:05PM
Mar-15-22 07:30AM
Mar-09-22 04:05PM
Feb-24-22 07:55AM
Feb-01-22 07:30AM
Jan-25-22 10:00AM
Jan-05-22 07:00AM
Dec-16-21 04:05PM
Dec-01-21 08:22AM
Nov-18-21 10:21AM
Nov-15-21 07:30AM
Nov-10-21 04:05PM
Nov-09-21 07:30AM
Nov-03-21 04:05PM
Oct-13-21 04:05PM
Oct-12-21 05:01AM
Oct-11-21 07:01AM
Oct-07-21 04:05PM
Sep-30-21 06:57PM
Aug-12-21 04:05PM
Aug-09-21 04:05PM
Aug-05-21 04:05PM
Jun-09-21 07:30AM
May-13-21 04:05PM
May-06-21 04:05PM
Apr-07-21 07:30AM
Mar-25-21 04:05PM
Mar-18-21 04:05PM
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio for the treatment of serious cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b/3 clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Delfini LisaChief Financial OfficerSep 11Option Exercise0.512,2911,17135,105Sep 13 04:06 PM
Delfini LisaChief Financial OfficerSep 11Sale2.207111,56434,394Sep 13 04:06 PM
Delfini LisaChief Financial OfficerAug 11Option Exercise0.512,2921,17133,496Aug 14 04:00 PM
Delfini LisaChief Financial OfficerAug 11Sale2.366821,61032,814Aug 14 04:00 PM
Delfini LisaChief Financial OfficerJul 11Option Exercise0.512,2921,17131,891Jul 12 04:29 PM
Delfini LisaChief Financial OfficerJul 11Sale2.346871,60831,204Jul 12 04:29 PM
Simon FarrellChief Commercial OfficerJun 20Option Exercise0.516,2503,19445,650Jun 21 04:00 PM
Delfini LisaChief Financial OfficerJun 12Option Exercise0.512,2911,17130,209Jun 14 04:28 PM
Delfini LisaChief Financial OfficerJun 12Sale2.646101,61029,599Jun 14 04:28 PM
Delfini LisaChief Financial OfficerMay 11Option Exercise0.512,2911,17128,480May 15 04:00 PM
Delfini LisaChief Financial OfficerMay 11Sale2.895621,62427,918May 15 04:00 PM
Delfini LisaChief Financial OfficerApr 11Option Exercise0.512,2921,17127,029Apr 12 05:02 PM
Delfini LisaChief Financial OfficerApr 11Sale1.848401,54526,189Apr 12 05:02 PM
Delfini LisaChief Financial OfficerMar 13Option Exercise0.512,2911,17125,629Mar 15 04:00 PM
Delfini LisaChief Financial OfficerMar 13Sale1.758921,56424,737Mar 15 04:00 PM
Simon FarrellChief Commercial OfficerMar 07Option Exercise0.5118,7509,58139,400Mar 08 04:00 PM
Delfini LisaChief Financial OfficerFeb 13Option Exercise0.5127,50014,05231,812Feb 15 04:01 PM
Delfini LisaChief Financial OfficerFeb 13Sale2.458,47420,76123,338Feb 15 04:01 PM